C4 Therapeutics, Inc.

Stage 3 · Topping · week 7

As of Oct 22, 2026, C4 Therapeutics is in Stage 3, the topping phase, now in week 7 (since Sep 8, 2026). It closed at $3.18, 31.9% below its 52-week high and above its 200-day average, which is rising.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. More about the company

$3.18

+2.45% today

$391M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is CCCC early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 15w

S2 17w

S4 38w

S3 14w

S2 26w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 2w → S4 15w → S1 4w → S2 17w → S3 10w → S4 3w → S1 9w → S4 38w → S1 11w → S2 7w → S3 14w → S4 4w → S2 26w → S3 6w current

Total tracked: 166 weeks across 14 stage runs.

CCCC among Biotechnology118th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…118	CCCCC4 Therapeutics, Inc.	Stage 3 · wk 7	76	+3.2%

vs 52W High

-31.9%

$1.71 lo$4.67 hi

31.9% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 7

1w13w26w

Week 7, distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

0.1%

200 DMA: $3.18 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.72x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+3.2%

-6.5%

+7.1%

YTD

+64.8%

+29.3%

Scan Membership

Breakout Watch

Latest: 2024-01-09

2 appearances in last 60 days. First seen: 2021-07-20.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 7 · Vol 0.72x

2026-10-21S3

Wk 7 · Vol 0.88x

2026-10-20S3

Wk 7 · Vol 1.59x

2026-10-19S3

Wk 6 · Vol 1.36x

2026-10-16S3

Wk 6 · Vol 1.04x

2026-10-15S3

Wk 6 · Vol 1.45x

2026-10-14S3

Wk 6 · Vol 1.37x

2026-10-13S3

Wk 6 · Vol 1.72x

2026-10-12S3

Wk 5 · Vol 0.67x

2026-10-09S3

Wk 5 · Vol 1.12x

2026-10-08S3

Wk 5 · Vol 1.27x

2026-10-07S3

Wk 5 · Vol 1.02x

Moving averages & range

50 DMA

$3.44

200 DMA

$3.18

52W High

$4.67

52W Low

$1.71

5D Low

$2.77

Resistance levels (recent highs)

20d High

$3.33

60d High

$4.27

120d High

$4.67

250d High

$4.67

Next resistance

+4.7%

to 20d High

ROE

-48.1%

Profit margin -289.4%

Dividend Yield

0.00%

P/B 1.6

C4 Therapeutics: quick answers

What stage is C4 Therapeutics in?

As of Oct 22, 2026, C4 Therapeutics (CCCC) is in Stage 3, the topping phase. It entered Stage 3 on Sep 8, 2026 and is in week 7. What the four stages mean

Is C4 Therapeutics in an uptrend?

Its uptrend has stalled. C4 Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 0.1% above its 200-day average, which is rising.

How far is C4 Therapeutics from its 52-week high?

C4 Therapeutics closed at $3.18 on Oct 22, 2026, 31.9% below its 52-week high of $4.67. Its 52-week low is $1.71.

How has C4 Therapeutics performed over the past year?

As of Oct 22, 2026, C4 Therapeutics is up 29.3% over the past year and up 64.8% so far in 2026.

Which sector and industry is C4 Therapeutics in?

C4 Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.